Trial · NCT03470545
Adverse events88
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 88
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Gastroenteritis viral | Infections and infestations | Mavacamten (MYK-461) | 0 | 123 | |
| serious | Gastroenteritis viral | Infections and infestations | Placebo | 1 | 128 | |
| serious | Infection | Infections and infestations | Mavacamten (MYK-461) | 1 | 123 | |
| serious | Infection | Infections and infestations | Placebo | 0 | 128 | |
| serious | Contusion | Injury, poisoning and procedural complications | Mavacamten (MYK-461) | 1 | 123 | |
| serious | Contusion | Injury, poisoning and procedural complications | Placebo | 0 | 128 | |
| serious | Forearm Fracture | Injury, poisoning and procedural complications | Mavacamten (MYK-461) | 1 | 123 | |
| serious | Forearm Fracture | Injury, poisoning and procedural complications | Placebo | 0 | 128 | |
| serious | Dehydration | Metabolism and nutrition disorders | Mavacamten (MYK-461) | 0 | 123 | |
| serious | Dehydration | Metabolism and nutrition disorders | Placebo | 1 | 128 | |
| serious | Rheumatoid arthritis | Musculoskeletal and connective tissue disorders | Mavacamten (MYK-461) | 0 | 123 | |
| serious | Rheumatoid arthritis | Musculoskeletal and connective tissue disorders | Placebo | 1 | 128 | |
| serious | SLE | Musculoskeletal and connective tissue disorders | Mavacamten (MYK-461) | 1 | 123 | |
| serious | SLE | Musculoskeletal and connective tissue disorders | Placebo | 0 | 128 | |
| serious | Cholesteatoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Mavacamten (MYK-461) | 0 | 123 | |
| serious | Cholesteatoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 128 | |
| serious | Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Mavacamten (MYK-461) | 0 | 123 | |
| serious | Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 128 | |
| serious | Syncope | Nervous system disorders | Mavacamten (MYK-461) | 3 | 123 | |
| serious | Syncope | Nervous system disorders | Placebo | 1 | 128 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03470545/events?page=4